文献速递肝胆胰外科围术期管理与 ERAS

可切除胰腺癌全身化疗的临床试验综述

Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
PubMed 文献 · JAMA Surg · 2021-01-01

本综述分析了所有关于可切除或已切除胰腺导管腺癌(PDAC)新辅助和辅助治疗的随机临床试验,聚焦试验设计、入组人群特征和长期结局。综述指出,mFOLFIRINOX辅助化疗是目前适合的已切除PDAC患者的标准治疗,但新辅助治疗的作用正在扩大;精准肿瘤学可能有助于个体化治疗。

要点

  • mFOLFIRINOX辅助化疗是适合的已切除PDAC患者当前标准治疗。
  • 新辅助治疗在可切除PDAC中的作用正在扩大,但部分患者后续无法手术。
  • 鼓励可切除PDAC患者入组临床试验。

核心结论

  • mFOLFIRINOX辅助化疗是目前适合的已切除PDAC患者的标准治疗,但新辅助治疗的作用正在扩大。
  • 精准肿瘤学可能有助于个体化治疗方案和顺序并改善结局。
  • 强烈鼓励可切除PDAC患者入组临床试验。

研究设计与样本

  • 本综述分析了所有研究可切除或已切除PDAC患者新辅助和辅助治疗的随机临床试验,聚焦试验设计、入组人群特征和长期结局。

主要发现

  • 现有可切除PDAC试验内部 validity 良好,但因入选标准严格而适用性可变。
  • PRODIGE 24试验的延长生存凸显了mFOLFIRINOX的成功和患者选择的重要性。
  • 新辅助和围手术期试验显示有希望的初步结果,但后续不符合手术条件的患者数量反映了该方法的局限性。
  • 在西方国家,新辅助与辅助治疗的直接比较迄今有限。
  • 利用基因组和体细胞检测可操作突变的精准肿瘤学有希望的初步结果,但对早期疾病和新辅助治疗的意义尚不清楚。

关键数值与推荐

  • 总生存期是这些试验的 criterion standard 终点,但无病生存期更可行、更接近且对指定干预更具特异性(代价是主观结局评估),因此在某些情况下是可接受的终点。

临床怎么用

  • 对适合的已切除PDAC患者,辅助化疗采用mFOLFIRINOX。
  • 考虑新辅助治疗时需注意部分患者后续无法手术。
  • 鼓励可切除PDAC患者参加临床试验。
  • 精准肿瘤学可能帮助个体化治疗,但早期疾病和新辅助治疗的意义未知。

局限性

  • 现有可切除PDAC试验因入选标准严格而适用性可变。
  • 新辅助和围手术期试验中部分患者后续不符合手术条件。
  • 西方国家新辅助与辅助治疗的直接比较有限。
  • 精准肿瘤学对早期疾病和新辅助治疗的意义尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adjuvant chemotherapy is the standard of care for resected pancreatic ductal adenocarcinoma (PDAC) based on level 1 evidence, but some studies suggest that a neoadjuvant approach (which is standard for borderline resectable PDAC) may be preferable for upfront resectable PDAC. An in-depth review was conducted of all randomized clinical trials that investigated neoadjuvant and adjuvant treatment of patients with resectable or resected PDAC, focusing on trial design, characteristics of enrolled population, and long-term outcomes. OBSERVATIONS: The existing resectable PDAC trials have good internal validity but variable applicability because of their restrictive eligibility criteria. In these trials, overall survival is the criterion standard end point, but disease-free survival is more feasible, proximate, and specific to the assigned intervention (at the cost of subjective outcome assessment) and thus an acceptable end point in certain contexts. The prolonged survival in the PRODIGE 24 trial highlights both the success of mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, and oxaliplatin) and the importance of patient selection. Neoadjuvant and perioperative trials have shown promising preliminary results; however, the number of patients who are not subsequently eligible for surgery reflects the limitations of this approach. Head-to-head comparisons of neoadjuvant and adjuvant treatments are limited to date in Western countries. Precision oncology with genomic and somatic testing for actionable mutations has promising preliminary results and may refine the management of PDAC, although the implications for early-stage disease and neoadjuvant therapy are unknown. CONCLUSIONS AND RELEVANCE: This review found that adjuvant chemotherapy with mFOLFIRINOX is currently the standard of care in fit patients with resected PDAC; however, the role of neoadjuvant treatment is expanding. Precision oncology may help individualize the treatment regimen and sequence and improve outcomes. Enrollment of patients with resectable PDAC in clinical trials is strongly encouraged.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Mavros MN, Moris D, Karanicolas PJ, et al. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review. JAMA Surg. 2021. PMID: 33787841. doi:10.1001/jamasurg.2021.0149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。